Biologic-Associated Hair and Nail Toxicities: Mechanisms, Clinical Features, and Management

Abstract

Biologic therapies have revolutionized the management of numerous autoimmune and inflammatory diseases by providing targeted immunomodulation. However, as their use has expanded, recognition of associated adverse effects, including hair and nail toxicities, has grown. These manifestations can be distressing, affect quality of life, and occasionally signal more serious underlying pathology. This review synthesizes current evidence on the epidemiology, mechanisms, risk factors, clinical features, diagnostic approaches, and management strategies for hair and nail toxicities linked to biologic agents. Special emphasis is placed on practical clinical insights and guideline-based recommendations to aid healthcare professionals in early recognition and optimal management of these complications.

Introduction

The advent of biologic agents has fundamentally altered the therapeutic landscape in rheumatology, dermatology, gastroenterology, and other specialties. By targeting specific cytokines, cell surface molecules, or immune pathways, biologics offer efficacy in controlling diseases such as rheumatoid arthritis, psoriasis, Crohn’s disease, and more. However, their targeted immunomodulation is not without consequence. Among the spectrum of adverse effects, hair and nail toxicities have garnered increasing attention due to their potential to impair patient well-being, adherence, and, in rare cases, indicate immune dysregulation. Understanding these adverse reactions is essential for clinicians involved in the care of patients receiving biologics.

Epidemiology / Disease Burden

The true incidence and prevalence of biologic-associated hair and nail toxicities remain incompletely characterized, with estimates varying depending on the agent, indication, and population. Studies report hair abnormalities in 1–13% of patients receiving anti-TNF agents, with nail changes less frequently described but increasingly recognized in post-marketing surveillance and case series. The disease burden is not trivial: alopecia or nail dystrophy can have significant psychosocial ramifications, particularly in chronic diseases requiring prolonged therapy. Moreover, these toxicities may contribute to treatment discontinuation or necessitate additional interventions, compounding healthcare resource utilization.

Pathophysiology

The mechanisms underlying hair and nail toxicities from biologics are multifactorial and incompletely elucidated. Disruption of cytokine networks critical for hair follicle cycling, such as TNF-α, IL-17, and IL-23 pathways, can precipitate hair loss or structural abnormalities. Paradoxical immune activation, as seen in anti-TNF-induced psoriasiform eruptions, may manifest as alopecia or nail changes. Immune checkpoint inhibitors, now classified as immuno-biologics, can induce autoimmune alopecia areata-like presentations. Some agents, by modulating keratinocyte proliferation or differentiation, may directly affect nail matrix biology. Genetic susceptibility and concomitant medications further modulate risk.

Risk Factors

Risk factors for developing hair and nail toxicities include female sex, underlying autoimmune disorders with pre-existing hair or nail involvement (e.g., psoriasis), prolonged exposure to biologics, and use of combination immunosuppressive regimens. Certain biologics, such as infliximab and adalimumab, have a higher propensity to induce these adverse events, particularly in genetically predisposed individuals. The presence of concomitant dermatological disease, prior episodes of drug-induced alopecia or nail dystrophy, and a personal or family history of autoimmune hair/nail disorders further elevate risk. Notably, pediatric and elderly populations may exhibit distinct susceptibility profiles.

Clinical Features

Hair toxicities range from diffuse telogen effluvium and patchy alopecia to scarring alopecia and trichorrhexis nodosa. Paradoxical induction or exacerbation of conditions such as alopecia areata and lichen planopilaris have been reported, particularly with anti-TNF and anti-IL-17 agents. Nail changes encompass pitting, onycholysis, Beau’s lines, paronychia, and subungual hyperkeratosis. Psoriasiform nail dystrophy is increasingly recognized as a paradoxical reaction with biologic therapies. The onset may be delayed, often emerging weeks to months after initiation, and may persist or worsen despite continued therapy. Importantly, these manifestations may mimic disease flares or infections, necessitating careful clinical evaluation.

Diagnosis

Diagnosis is primarily clinical, supported by a thorough drug history and exclusion of alternative etiologies such as nutritional deficiencies, thyroid dysfunction, or concomitant medications known to cause similar manifestations. Trichoscopy and nail dermoscopy can facilitate recognition of characteristic patterns. In select cases, scalp or nail matrix biopsy may be warranted to distinguish drug-induced changes from primary dermatologic conditions. Laboratory investigations may be necessary to rule out infection or systemic contributors. Multidisciplinary collaboration with dermatology is often beneficial in complex or refractory cases.

Treatment & Management

Management strategies are individualized based on severity, patient preference, and the necessity of ongoing biologic therapy. Mild cases may be managed conservatively with reassurance and symptomatic measures such as topical minoxidil or corticosteroids. For more severe or persistent toxicities, dose reduction, switching to an alternative biologic with a different mechanism of action, or temporary discontinuation may be considered. Treatment of underlying or paradoxical dermatologic conditions (e.g., topical or systemic therapies for psoriasiform eruptions) may be warranted. Patient education regarding the potential reversibility of most changes and the importance of early recognition is crucial.

Recent Advances / Emerging Therapies

Recent research has focused on elucidating the specific immunologic pathways implicated in biologic-induced hair and nail toxicities, paving the way for targeted preventive and therapeutic strategies. JAK inhibitors, for example, are being explored for their potential to treat both primary and drug-induced alopecia areata. Biomarker studies aim to identify patients at heightened risk, facilitating pre-emptive counseling and monitoring. Advances in trichoscopy and nail imaging enhance diagnostic precision, while novel biologic agents with more selective cytokine inhibition may offer improved safety profiles. Ongoing clinical trials will further inform best practices in this evolving field.

Guideline Recommendations

Current guidelines, including those from the American Academy of Dermatology and European League Against Rheumatism, emphasize the importance of baseline dermatologic assessment and regular monitoring for cutaneous adverse events in patients receiving biologics. Prompt recognition and documentation of hair and nail changes are encouraged, with referral to dermatology as appropriate. Decisions regarding biologic continuation should be individualized, balancing disease control with adverse event severity. Shared decision-making and patient education are integral to optimizing outcomes.

Conclusion

Hair and nail toxicities are increasingly recognized complications of biologic therapy, with significant implications for patient quality of life and therapeutic adherence. A thorough understanding of their epidemiology, pathophysiology, clinical features, and management is essential for healthcare professionals. Ongoing research and guideline refinement will continue to enhance the care of patients experiencing these adverse effects, ensuring optimal clinical outcomes in the era of biologic therapies.